ArticleChinese journal of integrative medicine2026
Efficacy, Safety, and Pharmacoeconomic Evaluation of Shiwei Longdanhua Capsules in Acute Exacerbation of Chronic Bronchitis with Phlegm-Heat Obstructing Fei (Lung): A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Control Trial.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy, safety, and pharmacoeconomic profile of Shiwei Longdanhua Capsules (SWLDH) for treating acute exacerbation of chronic bronchitis (AECB) patients with Chinese medicine (CM) syndrome of phlegm-heat obstructing Fei (Lung, PHOF).
methodsThis multicenter, randomized, double-blind, double-dummy, active-controlled trial enrolled AECB patients with PHOF syndrome across 14 centers in China from February 2023 to January 2024. Participants were randomized in a 3:1 ratio to the SWLDH and Feilike Capsules (FLK) groups. The SWLDH group received SWLDH (1.35 g) plus FLK placebo, while the FLK group received FLK (1.20 g) plus SWLDH placebo, administered orally 3 times daily for 14 d. The primary endpoint was the improvement rate of CM syndrome after 14-d treatment; the secondary endpoints included cough-related outcomes, CM symptom scores, quality of life, safety, and pharmacoeconomic outcomes.
resultsA total of 193 patients were enrolled in the study, with 144 in the SWLDH group and 49 in the FLK group. The improvement rate of CM syndrome after 14-d treatment was significantly higher in the SWLDH group than that in the FLK group (95.1% vs. 81.3%, P=0.006). SWLDH also significantly improved the cough disappearance or near-disappearance rate on day 14 (81.1% vs. 63.3%, P=0.011). For individual CM symptom efficacy, the improvement rate of cough was significantly higher in the SWLDH group than in the FLK group after 14-d treatment (89.3% vs. 77.6%, P=0.040). Both groups showed improvements in quality of life assessed by Leicester Cough Questionnaire scores, with no significant between-group differences. SWLDH showed a comparable safety profile with FLK and no discontinuations due to adverse events. Compared with FLK, SWLDH incurred an additional cost of 1,344.09 RMB per additional case of effective CM symptom improvement and an incremental cost of 202,733.75 RMB per quality-adjusted life year gained, which was below the willingness-to-pay threshold.
conclusionsSWLDH significantly improved CM symptoms, accelerated cough resolution, and enhanced quality of life in AECB patients with PHOF syndrome, with a favorable safety profile and cost-effectiveness. (Trial registration No. ChiCTR2200066665).
Indexed as
Identifiers
42747756What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.